Fundz

Xenon Pharmaceuticals Appoints Tucker Kelly as Chief Financial Officer

PUBLIC · XENEOct 16, 2025

Position

Chief Financial Officer

Company

Xenon Pharmaceuticals

Tucker Kelly
tkelly@xenon-pharma.com
BiotechnologyHealth Care

Description

Xenon Pharmaceuticals has announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and a member of its senior executive team. Kelly, with extensive strategic and commercial finance experience, will support the company's efforts in the anticipated commercialization of its lead candidate, azetukalner.

Quick answer

Xenon Pharmaceuticals Appoints Tucker Kelly as Chief Financial Officer (October 16, 2025).

Who is the new Chief Financial Officer at Xenon Pharmaceuticals?
Xenon Pharmaceuticals named Tucker Kelly Chief Financial Officer, announced October 16, 2025.
What did Xenon Pharmaceuticals announce on October 16, 2025?
Xenon Pharmaceuticals has announced the appointment of Tucker Kelly as Chief Financial Officer (CFO) and a member of its senior executive team. Kelly, with extensive strategic and commercial finance experience, will support the company's efforts in the anticipated commercialization of its lead candidate, azetukalner.
What does Xenon Pharmaceuticals do?
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need.
Which similar companies made leadership changes around the same time?
Nanopath (October 16, 2025), Eli Lilly and Company (October 16, 2025), Avita Medical (October 16, 2025) and Algorae Pharmaceuticals (October 15, 2025) also announced leadership changes within 45 days of Xenon Pharmaceuticals.

Source: Fundz verified event record.

Other recent leadership changes in Biotechnology and Health Care

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Xenon Pharmaceuticals, and when

A new leader at Xenon Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Xenon Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Xenon Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Xenon Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Xenon Pharmaceuticals

About

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. We have offices in Vancouver, British Columbia, and Boston, Massachusetts.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Xenon Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Ian
Likely contact at this company
••••••••@••••••••

See Ian's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Xenon Pharmaceuticals's next move

Learn about Strategic plan

Xenon Pharmaceuticals changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.